Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00034853
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : November 1, 2013
Information provided by:
Boehringer Ingelheim

Brief Summary:
To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)

Condition or disease Intervention/treatment Phase
Arthritis, Juvenile Rheumatoid Drug: meloxicam oral suspension Drug: naproxen oral suspension Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis
Study Start Date : December 2000
Actual Primary Completion Date : June 2003

Primary Outcome Measures :
  1. Responder rate by core set of outcome criteria (Juvenile Rheumatoid Arthritis Pediatric 30): global assessment disease activity; functional disability, number joints arthritis, limited motion; erythrocyte sedimentation rate; [ Time Frame: week 12 ]

Secondary Outcome Measures :
  1. Individual core set outcome criteria; final global assessment of efficacy; tolerability; AE incidence and intensity; withdrawals; acetaminophen consumption; safety labs: physical examination; hospitalization for gastrointestinal (GI) SAE, GI AE [ Time Frame: weeks 4, 8, 12, 18, and 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of juvenile idiopathic arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria; pauciarthritic, extended pauciarthritic, or polyarthritic current course of disease;
  • active arthritis of at least 2 joints
  • at least 2 other abnormal variables of the 5 remaining core set parameters
  • require nonsteroidal anti-inflammatory drugs (NSAIDs)
  • children aged 2-17 years

Exclusion Criteria:

  • systemic course of juvenile idiopathic arthritis
  • all rheumatic conditions not included in inclusion criteria; any clinical finding or abnormal clinically relevant lab (not due to JIA) that could interfere with conduct of clinical trial
  • weight of 9 kg or less
  • pregnancy or breast feeding
  • females of childbearing potential who are sexually active and not using adequate contraception for at least 3 mos prior to and for duration of study
  • history of bleeding disorder, gastrointestinal bleeding, or cerebrovascular bleeding
  • peptic ulcer past 6 months
  • more than 1 disease modifying anti-rheumatic drug (DMARD) or change in DMARD during 3 months prior
  • change corticosteroids during 1 month prior
  • systemic corticosteroids greater than 10 mg/d, hydroxychloroquine greater than 10/mg/d, cyclosporine greater than 5 mg/kg/d., methotrexate greater than 15 mg/m2/wk, cytotoxic agents, gold, D-penicilamine, sulfasalazine, glucosamine, and investigational products
  • etanercept during 1 month prior; infliximab during 2 months prior; intra-articular corticosteroids during 1 month prior
  • patients requiring concomitant other NSAID including topical (excluding ophthalmic)
  • requirement for use of other NSAIDs, anticoagulants, phenothiazine, lithium, or ACTH
  • insufficient effect or intolerability to naproxen or meloxicam
  • known or suspected hypersensitivity to trial meds or their excipients
  • requirement of chronic H2 antagonist
  • history of asthma, nasal polyps, angioneurotic edema, or urticaria with aspirin or NSAIDs
  • planned surgical procedures during study
  • investigational drug exposure during this trial or within 30 days (or 6 half lives, whichever greater) prior
  • previous participation in this trial
  • patients with known drug or alcohol abuse
  • patient, parent or legal representative unable to understand and to comply with protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00034853

Show Show 37 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00034853    
Obsolete Identifiers: NCT00274482
Other Study ID Numbers: 107.235
First Posted: May 3, 2002    Key Record Dates
Last Update Posted: November 1, 2013
Last Verified: October 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase 2 Inhibitors